Advanced Biomed Inc. (NASDAQ:ADVB) Short Interest Update

Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 15,397 shares, an increase of 73.5% from the June 15th total of 8,876 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily volume of 14,727 shares, the short-interest ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Get Advanced Biomed alerts:

View Our Latest Report on ADVB

Advanced Biomed Trading Up 1.0%

Shares of Advanced Biomed stock opened at $5.25 on Friday. The company’s 50-day simple moving average is $4.65. Advanced Biomed has a one year low of $3.61 and a one year high of $16.13. The company has a market cap of $8.66 million, a price-to-earnings ratio of 1.09 and a beta of 0.52.

Advanced Biomed (NASDAQ:ADVB – Get Free Report) last issued its quarterly earnings results on Saturday, May 16th. The company reported ($0.38) earnings per share (EPS) for the quarter.

About Advanced Biomed

(Get Free Report)

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.

Featured Stories

• Five stocks we like better than Advanced Biomed
• The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet
• Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
• Has Broadcom Become Too Expensive for Its AI Story?
• Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.